drugset / Trial / NCT01607671

Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%

NCT01607671 ↗

Phase 1 Withdrawn Fraser Health
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the progression or improves recovery of patients who are randomly assigned to treatment versus standard of care.

Timeline

Start
2012-06
Primary completion
2013-11
Completion
2013-11

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to recruit participants from recruiting sites.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Timolol Other / unclassified 0.5 % Topical